Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.

Kang BW, Lee D, Chung HY, Han JH, Kim YB.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1835-43. doi: 10.1007/s00432-013-1503-4. Epub 2013 Sep 5.

PMID:
24005419
2.

CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.

Ha SY, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.

Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4.

PMID:
24306658
3.

Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.

Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Kwon MJ, Nam SJ, Im YH, Shin YK, Choi YL.

Br J Cancer. 2012 Feb 28;106(5):923-30. doi: 10.1038/bjc.2012.11. Epub 2012 Jan 31.

4.

Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.

Kang BW, Jeong JY, Chae YS, Lee SJ, Lee YJ, Choi JY, Lee IK, Jeon SW, Bae HI, Lee DK, Kwon OK, Chung HY, Yu W, Kim JG.

Cancer Chemother Pharmacol. 2012 Nov;70(5):735-41. doi: 10.1007/s00280-012-1964-1. Epub 2012 Sep 7.

PMID:
22955258
5.

Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.

Lee D, Suh YL, Park TI, Do IG, Seol HJ, Nam DH, Kim ST.

J Surg Oncol. 2013 May;107(6):646-52. doi: 10.1002/jso.23249. Epub 2012 Aug 23.

PMID:
22926763
6.

Overexpression of CD151 predicts prognosis in patients with resected gastric cancer.

Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR, Xu WX.

PLoS One. 2013;8(3):e58990. doi: 10.1371/journal.pone.0058990. Epub 2013 Mar 22.

7.

Prognostic significance of CD151 overexpression in non-small cell lung cancer.

Kwon MJ, Seo J, Kim YJ, Kwon MJ, Choi JY, Kim TE, Lee DH, Park S, Shin YK, Han J, Choi YL.

Lung Cancer. 2013 Jul;81(1):109-16. doi: 10.1016/j.lungcan.2013.03.014. Epub 2013 Apr 6.

PMID:
23570797
8.

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.

Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J.

Hepatology. 2009 Feb;49(2):491-503. doi: 10.1002/hep.22639.

PMID:
19065669
9.

Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.

Koo DH, Ryu MH, Ryoo BY, Lee SS, Moon JH, Chang HM, Lee JL, Kim TW, Kang YK.

Gastric Cancer. 2012 Jul;15(3):305-12. doi: 10.1007/s10120-011-0117-2. Epub 2011 Dec 10.

PMID:
22160244
10.

Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.

Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A.

J Egypt Natl Canc Inst. 2007 Jun;19(2):147-57.

11.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

12.

Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.

Inoue K, Nakane Y, Kogire M, Fujitani K, Kimura Y, Imamura H, Tamura S, Okano S, Kwon AH, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H.

Eur J Surg Oncol. 2012 Feb;38(2):143-9. doi: 10.1016/j.ejso.2011.11.009. Epub 2011 Dec 9.

PMID:
22154885
13.

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K.

Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29.

14.

Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study.

Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hasegawa S, Aoyama T, Hayashi T, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J.

Ann Surg Oncol. 2014 Jun;21 Suppl 3:S385-9. doi: 10.1245/s10434-014-3615-8. Epub 2014 Mar 5.

PMID:
24595801
15.

Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment.

Kadowaki S, Komori A, Narita Y, Nitta S, Yamaguchi K, Kondo C, Taniguchi H, Takahari D, Ura T, Ando M, Muro K.

Int J Clin Oncol. 2014 Aug;19(4):656-61. doi: 10.1007/s10147-013-0610-1. Epub 2013 Sep 3.

PMID:
23999902
16.

The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.

Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, Tanaka T, Ito M, Kurumatani N, Nakajima Y.

Ann Surg Oncol. 2013 Aug;20(8):2647-54. doi: 10.1245/s10434-013-2926-5. Epub 2013 Mar 6.

PMID:
23463091
17.

Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.

Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ.

Histol Histopathol. 2000 Apr;15(2):455-62.

PMID:
10809364
18.

Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.

Migita K, Nashimoto A, Yabusaki H, Matsuki A, Aizawa M.

Int J Clin Oncol. 2016 Feb;21(1):102-9. doi: 10.1007/s10147-015-0851-2. Epub 2015 May 28.

PMID:
26017926
19.

Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.

Lee SJ, Sohn TS, Lee J, Park SH, Park JO, Lim DH, Park YS, Lim HY, Choi MG, Lee JH, Bae JM, Kim S, Kang WK.

Anticancer Res. 2014 Nov;34(11):6585-91.

PMID:
25368262
20.

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer.

Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F, Sundar S.

Br J Cancer. 2011 May 10;104(10):1611-8. doi: 10.1038/bjc.2011.80. Epub 2011 Apr 19.

Supplemental Content

Support Center